Join
Live feed
·
PRReleasevia Quantisnow
Nkarta Inc. logo

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
NKTX· Nkarta Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NKTX (Nkarta Inc.) and more on Quantisnow.